Efficacy of a Portable, Audible‐Only Electromyography Device in the Treatment of Spasmodic Dysphonia
B. Jeffcoat,J. Schweinfurth
DOI: https://doi.org/10.1097/MLG.0b013e3181639b7e
IF: 2.97
2008-05-01
The Laryngoscope
Abstract:INTRODUCTION Adductor spasmodic dysphonia (SD) is the result of involuntary over-contraction of the thyroarytenoid muscles during speech. Treatment is directed at limiting the action of these muscles. Currently, Clostridium botulinum bacterial toxin (BOTOX, Allergan, Inc., Irvine, CA) is an effective treatment option when injected into the thyroarytenoid muscle.1–4 BOTOX blocks the release of acetylcholine at the neuromuscular junctions causing denervation of the thyroarytenoid muscle.5 Treatment with BOTOX typically lasts 3 to 4 months. Symptoms gradually return, necessitating reinjection. Electromyography (EMG) monitoring has become an essential component in the identification of the thyroarytenoid muscles during BOTOX injection using the percutaneous approach. Many practitioners have relied on the services of a neurologist to interpret the EMG action potentials for proper placement of the injection. We propose using a handheld, audibleonly EMG device (Fig. 1) as an efficient and safe method for identification of the thyroarytenoid muscle for injection of BOTOX. To evaluate the efficacy of our proposed method, we reviewed the charts of 38 patients treated with intramuscular BOTOX injections over a 3-year period. Inclusion criteria was a diagnosis of adductor SD which was confirmed by functional endoscopic examination, failure to respond to speech therapy, and voice improvement to “normal” after at least three injections during the study period. Exclusion criteria included non-adductor type SD and patients who received less than three total injections during the study period. Using the handheld, audible-only EMG monitor, the senior author performed all injections. Of the 38 patients, 13 met our selection criteria. A “missed” injection was defined as no improvement in voice quality subjectively or objectively within 2 weeks following the injection. A “successful” injection was defined as subjective or objective improvement in voice quality within 2 weeks following the injection for a duration of at least 1 month. The injection technique involves the introduction of a 27-gauge, Teflon-coated, monopolar needle (DuPont, Wilmington, DE) through the skin overlying the superior edge of the cricoid, lateral to midline. The needle is then advanced through the cricothyroid membrane and directed superiorly and laterally into the vocal fold toward the thyroarytenoid muscles. We used the portable EMG device to audibly monitor muscle activity during the procedure. Thyroarytenoid location is confirmed by increased action potential density during phonation which is audibly interpreted by the operator. Once the position is confirmed, BOTOX is injected into the thyroarytenoid muscle. In the 13 patients that met our selection criteria, there were a total of 113 injections. Twenty patients were excluded because they did not have at least three injections during the chart review. Five patients were excluded because they had non-adductor SD. Twelve of the 13 patients included had at least one bilateral injection. There were 13 “missed” injections for a successful injection rate of 88.5%. One patient was noted to have four missed injections, all on the same side. We are unsure as to the etiology of the continued “missed” injections by this patient, but propose that this may be due to escalating dose requirements, BOTOX concentration, or failure to treat the specific symptom, causing muscle fibers among the From the Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, Mississippi, U.S.A. Editor’s Note: This Manuscript was accepted for publication November 29, 2007. Send correspondence to Benjamin T. Jeffcoat, MD, Department of Otolaryngology and Communicative Sciences, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A. E-mail: bjeffcoat@ent. umsmed.edu